INKT MINK THERAPEUTICS INC

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit  or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Investor Contact

917-362-1370

Media Contact

781-674-4428



EN
30/10/2023

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 F...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and ...

July 31, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Frontiers in Immunology Publication Highli...

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefinin...

July 15, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Publication of Complete Remission Followin...

MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another landmark case in , following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy. Complete remission after ...

July 11, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit  and enter the 16-digit control numbe...

June 10, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT...

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced it has been awarded a grant from the National Institute of Allergy and Infectious Diseases (N...

June 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch